- NEWS
Waning COVID super-immunity raises questions about Omicron
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-021-03674-1
References
Goldberg, Y. et al. Preprint at medRxiv https://www.medrxiv.org/content/10.1101/2021.12.04.21267114v1 (2021).
Wilhelm, A. et al. Preprint at medRxiv https://www.medrxiv.org/content/10.1101/2021.12.07.21267432v3 (2021).
Cele, S. et al. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.08.21267417v1 (2021).
Roessler, A. et al. Preprint at medRxiv https://www.medrxiv.org/content/10.1101/2021.12.08.21267491v1 (2021).
Stamatatos, L. et al. Science 372, 1413–1418 (2021).
Cho, A. et al. Nature https://doi.org/10.1038/s41586-021-04060-7 (2021).
Wang, Z. et al. Nature 595, 426–431 (2021).
Schmidt, F. et al. Nature https://doi.org/10.1038/s41586-021-04005-0 (2021).
Gazit, S. et al. Preprint at medRxiv https://www.medrxiv.org/content/10.1101/2021.08.24.21262415v1 (2021).